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Three mutants of Lactococcus lactis subsp. lactis MG1363, termed EthR, DauR, and RhoR, were selected for
resistance to high concentrations of ethidium bromide, daunomycin, and rhodamine 6G, respectively. These
mutants were found to be cross resistant to a number of structurally and functionally unrelated drugs, among
which were typical substrates of the mammalian multidrug transporter (P-glycoprotein) such as daunomycin,
quinine, actinomycin D, gramicidin D, and rhodamine 6G. The three multidrug-resistant strains showed an
increased rate of energy-dependent ethidium and daunomycin efflux compared with that of the wild-type strain.
This suggests that resistance to these toxic compounds is at least partly due to active efflux. Efflux of ethidium
from the EthR strain could occur against a 37-fold inwardly directed concentration gradient. In all strains,
ethidium efflux was inhibited by reserpine, a well-known inhibitor of P-glycoprotein. lonophores which
selectively dissipate the membrane potential or the pH gradient across the membrane inhibited ethidium and
daunomycin efflux in the wild-type strain, corresponding with a proton motive force-driven efflux system. The
ethidium efflux system in the EthR strain, on the other hand, was inhibited by ortho-vanadate and not upon
dissipation of the proton motive force, which suggests the involvement of ATP in the energization of transport.
The partial inhibition of ethidium efflux by ortho-vanadate and nigericin in the DauR and RhoR strains suggest
that a proton motive force-dependent and an ATP-dependent system are expressed simultaneously. This is the
first report of an ATP-dependent transport system in prokaryotes which confers multidrug resistance to the
organism.
Multidrug resistance (MDR) is the intrinsic or acquired
resistance of cells to various structurally and functionally
unrelated toxic compounds. For various mammalian cells, it
has been established that MDR is the result of active extrusion
of drugs from the cells, a process that is catalyzed by an
ATP-dependent transport protein termed P-glycoprotein or
MDR1 (14). P-glycoprotein confers resistance to vinca alka-
loids, anthracyclines, actinomycin D, valinomycin, gramicidin
D, and phosphonium ions (4, 7, 9). P-glycoprotein is classified
among members of the ATP-binding cassette (ABC) proteins
(15) or traffic ATPases (26), to which belong prokaryotic and
eukaryotic transport systems that facilitate either uptake or
extrusion of substrates. Because of the importance of MDR in
the failure of drug-based treatment of cancers and parasital
infections, most attention has been focused on eukaryotic
MDR systems. Recently, however, several MDR-like systems
in both gram-positive (31, 42) and gram-negative (11, 20, 23)
bacteria as well as in archaea (27) have been described. The
occurrence of acquired resistance in bacteria, and especially in
pathogenic bacteria like enterococci, staphylococci (35), and
Mycobacterium tuberculosis (3), also poses serious problems to
public health. MDR in these organisms is believed to be the
result of active extrusion by broad-specificity transport systems.
Resistance of bacteria to the ethidium ion has been known
for a long time (16). Ethidium readily crosses the membrane by
passive diffusion and intercalates between the bases of
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polynucleotides, thereby exerting its growth-inhibitory and
mutagenic effects. The presently characterized bacterial
ethidium resistance mechanisms are all membrane-located
extrusion systems. They can be divided into two homology
groups. To the first group belong several tetracycline and other
antibiotic resistance efflux systems, multidrug effiux systems,
and sugar uptake systems (2, 37). Recently, a mammalian
vesicular amine transporter was added to this group (22).
These proteins have either 12 or 14 putative membrane-
spanning helices, and a few of these carriers have been shown
to catalyze secondary transport (reviewed in references 21 and
32). The second group includes the products of highly similar
MDR genes from various Staphylococcus species and a methyl
viologen resistance determinant from Escherichia coli (8). The
polypeptides of this group have only four putative membrane-
spanning helices and are probably also proton gradient-driven
extrusion systems. The ethidium efflux systems of both homol-
ogy groups have different specificities, but all confer cross-
resistance to or catalyze efflux of unrelated compounds, like
acriflavine, phosphonium ions, quaternary ammonium ions,
aminoglycosides, rhodamine 6G, and chloramphenicol (8, 25,
31, 39).
In this paper we describe the isolation of three MDR
mutants of Lactococcus lactis. Characterization of the strains
indicates that transport of ethidium and daunomycin in L.
lactis can be mediated by two different systems that differ in
their mode of energization, i.e., a proton motive force (Ap)-
and an ATP-dependent system.
MATERIALS AND METHODS
Growth and preparation of organisms. L. lactis MG1363 was
grown at 30°C in medium A, which contained (per liter) 10 g of
tryptone, 10 g of Lab-Lemco powder (Oxoid, Basingstoke,
6957
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England), 5 g of yeast extract, 2 g of K2HPO4, 0.2 g of MgSO4,
and 35 mg of MnSO4, adjusted to pH 6.4 with HCl. Sterile 25
mM glucose or 25 mM galactose plus 10 mM L-arginine was
added separately.
For experiments with washed cell suspensions, exponentially
growing cultures were harvested and washed three times in 50
mM potassium phosphate, pH 7.0, supplemented with 5 mM
MgSO4. For inhibitor studies with ortho-vanadate, potassium
phosphate was replaced by potassium-HEPES [4-(2-hydroxy-
ethyl)-1-piperazinethane-sulfonate] at equimolar concentra-
tions. When necessary, cells were de-energized by incubation
for 30 min with 10 mM 2-deoxyglucose at 30°C followed by
three washing steps in the appropriate buffer.
Selection of drug-resistant mutants. Mutants of L. lactis
were isolated by selecting for growth in medium supplemented
with the toxic compound. Small amounts of exponentially
growing cultures were transferred to medium containing an
increased concentration of the toxic compound, after which
this step was repeated with stepwise increasing concentrations.
The final concentrations used were 200 puM ethidium bromide,
200 puM daunomycin, or 100 puM rhodamine 6G, and the
corresponding mutants were termed EthR, DauR, and RhoR,
respectively.
Determination of growth rate. The growth rate was deter-
mined in sterile low-protein-binding microplates (Greiner,
Frickenhausen, Germany). Aliquots of 250 p,1 of medium A
with various concentrations of different drugs were inoculated
with exponential growing cultures of the wild-type and mutant
strains of L. lactis. Growth was monitored by measuring the
A690 every 10 min in a multiscan photometer (Titertek Multi-
skan MCC/340 MKII; Flow Laboratories, Lugano, Switzer-
land). Growth rates were determined by nonlinear least-
squares fitting of the absorbance data to an equation
describing bacterial growth (43).
Ethidium eftlux. (i) A washed and de-energized cell suspen-
sion (0.2 mg of protein per ml) was incubated at 30°C with 5
,uM ethidium bromide and after 2 h was energized with glucose
(25 mM). At various times 0.75-ml samples were centrifuged
for 3 min at maximal speed (15,000 x g) in an Eppendorf
centrifuge. Supernatant (0.5 ml) was carefully pipetted off and
diluted into 1.5 ml of buffer containing a 0.1 mM concentration
of base pairs of fragmented calf thymus DNA (prepared as
described below). The fluorescence of this solution was mea-
sured with excitation and emission wavelengths of 500 and 580
nm, respectively, using slit widths of 5 and 10 nm, respectively.
Fluorescence was measured with a Perkin-Elmer LS 50B
fluorometer with computer-controlled data acquisition and
storage. A calibration curve with ethidium concentrations in
the range of 0 to 10 ,uM was found to be linear and was used
to estimate the concentration in the supernatant. (ii) Ethidium
efflux was also estimated from the fluorescence of the
ethidium-polynucleotide complex in the cell. Ethidium displays
approximately a 10-fold increase in fluorescence quantum yield
upon binding to DNA or RNA (19). This property was used to
monitor indirectly the intracellular ethidium concentration
(18, 24). A washed cell suspension (0.2 mg of protein per ml)
was incubated for 10 min with 10 ,uM ethidium bromide at
30°C to allow the ethidium to diffuse across the membrane.
Ethidium efflux was initiated by the addition of glucose (25
mM). Fluorescence was integrated every 0.5 s with excitation
and emission wavelengths of 500 and 580 nm, respectively. No
corrections were made for light scatter or absorption by cells,
since these parameters varied only slightly during the course of
an experiment.
Free internal ethidium concentration. The free intracellular
ethidium concentration was estimated from the ethidium
fluorescence in cells, assuming rapid equilibration between
ethidium bound to polynucleotides and the internal pool of
free ethidium (40). Cell suspensions were de-energized with 10
mM 2-deoxyglucose, and the transmembrane ion gradients
were dissipated with nigericin (1 ,uM) plus valinomycin (1 p.M)
in order to prevent accumulation or efflux. Subsequently, the
cells were diluted to 0.2 mg of cell protein per ml in 50 mM
potassium-HEPES-5 mM MgSO4 (pH 7.0), containing various
concentrations of ethidium bromide (0.25 to 20 p,M). The total
fluorescence (FTOT) of the cell suspension with ethidium is
the sum of the background fluorescence due to light scatter
and/or absorption by cells (FO), the intrinsic ethidium fluores-
cence (FETH), and the enhanced fluorescence of ethidium due
to the binding to polynucleotides (FBOUND). FBOUND can
then be calculated according the equation FBOUND = FTOT -
FETH - F Within certain limits, FBOUND is linearly related to[EthBOUN ] with a fluorescence constant KF-BOUND. Binding
of ethidium to polynucleotides and the resulting fluorescence





KD + [EthFREEIIN (1)
where FBOUND-MAX represents the fluorescence enhancement
from the maximal amount of ethidium bound to polynucleo-
tides and KD is the dissociation constant. FBOUND was calibrated
as a function of the free external ethidium concentration
([Eth OFREUT) at steady state, assuming that [EthF ]OUT
= [Eth' ]IN, [EthFREE]ouT was measured in the supernatant
fraction as described under "Ethidium eflux" above. KD and
FBOUND-MAX were determined by nonlinear least-squares
fitting of equation 1 to the calibration data. Rearranging
equation 1 gives
[EthFREEIIN = FBOUND * KD
FBOUND1MAX - FBOUND
(2)
From equation 2 and the fitted values for FBOUND-MAX and
KD, [EthlE]IN can be calculated from the observed fluores-
cence (FBOUND). For the calculations a specific internal vol-
ume of 3.6 ,l/mg of cell protein was used (33).
Preparation of fragmented calf thymus DNA. Calf thymus
DNA (Sigma Chemical Co., St. Louis, Mo.) was dissolved in
water and sonicated 10 times for 15 s each with an MSE
Soniprep probe-sonicator at an amplitude of 6 p.m with the
tube submerged in ice-water (6). The solution was filtered
through an Amicon cellulose nitrate filter with a pore size of
0.2 p.m. The base pair concentration was calculated from the
A260, using an extinction coefficient of 13.3 mM-' * cm-'.
Materials. Ethidium bromide was obtained from Merck,
Darmstadt, Germany. Daunomycin (daunorubicin) and reser-
pine were obtained from Sigma Chemical Co. All other
chemicals were reagent grade and obtained from commercial
sources.
RESULTS
The MDR phenotype of L. laetis mutants. Three L. lactis
MG1363 mutants, termed EthR, DauR, and RhoR, were iso-
lated from liquid cultures growing at 200 p.M ethidium bro-
mide or daunomycin or at 100 p.M rhodamine 6G, respectively.
Cross-resistance was tested for a number of toxic compounds
whose toxicities were established on agar plates. A wild-type
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FIG. 1. Cross-resistance ofL. lactis mutants resistant to ethidium bromide, daunomycin, and rhodamine 6G. L. lactis subsp. lactis MG1363 (wild
type) (0) and the mutants EthR (0), DauR (V), and RhoR (V) were grown on medium A in the presence of different concentrations of ethidium,
rhodamine 6G, or daunomycin. The relative growth rate is plotted as a function of the drug concentration. The actual growth rates of the various
strains with no drug varied between 0.9 and 1.1 h-1.
culture was confluently plated, and filter discs containing a
high concentration of a toxic compound were placed on top of
the agar. Compounds which caused large halos, indicative of
growth inhibition, were selected for further analysis. Results
with three compounds that caused a clear difference in growth
rate between the wild-type strain and the isolated mutants are
shown (Fig. 1). The mutants were cross resistant to ethidium,
daunomycin, and rhodamine 6G but also to a number of other
unrelated drugs, including gramicidin D, actinomycin D, and
quinine (data not shown). In fact, irrespective of the selective
agent, the mutants were resistant to a similar set of toxic
compounds, which is a clear indication for an MDR phenotype
in L. lactis.
Ethidium efflux from L. lactis cells. Ethidium effiux was
assayed directly by measuring the ethidium concentration in
the medium during the course of a transport experiment. The
internal ethidium concentration has been calculated from the
difference between the concentrations of total and external
ethidium. Ethidium efflux was observed upon energization of
L. lactis wild-type strain MG1363 and EthR (Fig. 2). The initial
efflux rates, which were determined by taking the slope (tan-
gent) of the line fitting the initial fluorescence decrease, is
approximately fivefold higher for EthR than for the wild-type
strain. Ethidium efflux was also measured indirectly by moni-
toring the fluorescence of the intracellular ethidium-polynu-
cleotide complex. The fluorescence intensity after addition of
ethidium and before addition of the energy source was nor-
malized to 100%. This fluorescence reflects the transport of
ethidium across the cytoplasmic membrane and the rapid
binding equilibrium of intracellular ethidium with DNA and
RNA. Energization of the ethidium-incubated cells led to a
decrease in fluorescence. The mutant strains of L. lactis have
an increased ethidium efflux relative to that of the wild-type
strain (Fig. 3). The initial ethidium efflux rates for the EthR,
DauR, and RhoR strains were approximately seven-, five-, and
threefold higher, respectively, than that for the wild-type
strain. The difference in the stimulation of the efflux rate
inferred from direct (Fig. 2) and indirect (Fig. 3) measure-
ments is most likely due to the different ethidium concentra-
tions at which transport was assayed. The differences in the
ethidium efflux rates correspond to the differences in ethidium
sensitivities of the various strains (Fig. 1). The data suggest
that ethidium resistance is indeed caused by an active efflux
process.
Ethidium efliux against a concentration gradient. If
ethidium efflux is mediated by an energy-dependent transport
process, efflux should occur against a concentration gradient.
The free internal ([EthFREE]IN) and external ([EthFEE]OUT)
ethidium concentrations were studied in the course of an efflux
assay. The external free ethidium concentration ([EthFREE]OIT)
can be measured directly from the supernatant fraction of a
cell suspension. The internal free ethidium concentration
([Eth F-u]IN) can be estimated from the fluorescence intensity
of the polynucleotide-bound ethidium as described in Materi-
als and Methods. The total fluorescence (FTOT) was measured
by incubating de-energized cells (treated with valinomycin and
nigericin) for 3 h with different concentrations of ethidium
bromide. From the calibration curve of EthR, a maximal
fluorescence (FBOUND-MAX) of 45.6 and a dissociation con-
stant (KD) of 1.05 ,uM were calculated. These values were used
to estimate [EthFll]IN and [EthFIE]OU during the course
of an efflux experiment (Fig. 4). Upon energization with
glucose, RthEE IN decreased from 1.7 to 0.12 p,M, whereas
[EthF ]OuT increased from 1.7 to 4.4 ,uM, resulting in a
37-fold inwardly directed ethidium concentration gradient. In a
comparable experiment with the wild-type strain, the steady-
state [EthFREI]IN and [EthFREEOUT were 0.75 and 3.75 ,uM,
























FIG. 2. Ethidium efflux from whole cells: direct measurement of
ethidium concentration. Ethidium efflux from cells of L. lactis subsp.
lactis MG1363 (wild type) (0) and EthR (0) preincubated for 2 h with
5 FiM ethidium bromide was monitored after energization with glucose
(25 mM). The internal ethidium concentration was calculated from the
difference between the total amount added and the concentration
measured in the supernatant fraction.
concentration gradient. These observations indicate that
ethidium efflux is mediated by energy-dependent processes.
Inhibition by reserpine. Reserpine is known as a potent
inhibitor of the MDR1 P-glycoprotein and of the Bacillus
subtilis MDR carrier (4, 31). Cells were preincubated with
reserpine (10 ,ug/ml) prior to the addition of ethidium. Reser-
pine inhibited ethidium efflux completely in the wild-type and
DauR strains (Fig. 5A, RES) and RhoR (data not shown) and
partially in EthR (Fig. 6A, RES). Energization of L. lactis cells
leads to the generation of an electrical potential (AiJi; inside
negative) which pulls the cationic ethidium to the inside, and the
ethidium concentration gradient ([EthFEIN/[EthFREE]OUT)
will become in equilibrium with the A+i. The enhanced increase
in ethidium fluorescence upon inhibition of the drug efflux
pumg by reserpine as observed for the wild-type, DauR, and
Rho strains (Fig. 5A; data not shown) is consistent with such
a mechanism, i.e., passive equilibration of ethidium with the
membrane potential. The absence of this phenomenon in EthR
cells suggest that ethidium efflux in this strain is not completely
inhibited by reserpine.
Presence of a secondary drug extrusion system. To establish
the driving force for ethidium efflux in L. lactis, ionophores
were used to selectively dissipate the components of Ap.
Dissipation of the proton gradient (ApH) by the electroneutral
proton/potassium antiporter nigericin or by the addition of the
weak acid potassium acetate inhibited ethidium efflux in the
wild-type and DauR strains (Fig. SA, NIG) and in the RhoR
strain (data not shown). These results indicate that the ApH is
a driving force for ethidium efflux. Addition of the potassium
ionophore valinomycin enhanced the efflux of ethidium in all
strains tested (Fig. 5A and 6A, VAL). Valinomycin dissipates
the As, with a concomitant increase in the ApH (28). This
decrease in the A* will lower the ethidium influx and/or
stimulate the efflux irrespective of whether the Ap is directly
involved in the efflux via the transport protein(s). Indications
for the involvement of the A*4 in the ethidium efflux process
were obtained from ethidium uptake experiments in cells in
which the ethidium efflux pump was inactivated. Cell suspen-
sions were energized with glucose and incubated at room
temperature in the presence or absence of reserpine or nigeri-
cin. Uptake was initiated upon the addition of ethidium
bromide (Fig. 5B). Ethidium uptake in reserpine-treated cells
was higher than that in nigericin treated cells (ApH poised to
zero), indicating that the Aq; is involved in ethidium efflux.
Taken together, the results suggest that ethidium efflux in
wild-type cells is mediated by a secondary transport system and
that both components of Ap function as a driving force.
Presence of a primary drug extrusion system. In contrast to
its effect on the wild-type, DauR, and RhoR strains, nigericin
had only a minor effect on ethidium efflux in EthR (Fig. 6A,
NIG). Dissipation of Ap by protonophores [SF2487, carbonyl
cyanide p-(trifluoromethoxy)-phenylhydrazone (FCCP), and
carbonyl cyanide m-chlorophenylhydrazone] or valinomycin
plus weak acids like potassium acetate also did not significantly
affect ethidium efflux in EthR (data not shown). These obser-
vations suggest a mechanism of energy coupling to ethidium
effiux in EthR that is different from that in the wild-type, DauR,
and RhoR strains. To analyze whether ethidium efflux was
coupled to ATP hydrolysis, the effects of various ATPase
inhibitors on ethidium transport were examined. For this
purpose, cells were preenergized with 10 mM L-arginine and
preincubated with different ATPase inhibitors. Assays were
started by the addition of 10 ,iM ethidium bromide. ortho-
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FIG. 3. Ethidium efflux from whole cells: indirect measurement of
ethidium concentration. Ethidium at a final concentration of 10 ,uM
was added to cell suspensions of L. lactis subsp. lactis MG1363 (wild
type), EthR, DauR, and RhoR. After 10 min of equilibration, the cells
were energized by adding 25 mM glucose, and ethidium efflux was
monitored by measuring the fluorescence decrease. The fluorescence
intensity after the addition of ethidium and before the addition of the
energy source was normalized to 100%.
J. BAcrIERIOL.
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FIG. 4. Ethidium efflux against a concentration gradient. Deoxy-
glucose-treated cells of L. lactis subsp. lactis EthR were incubated with
ethidium (5 ,uM) in the presence of valinomycin (1 ,uM) plus nigericin
(1 jiM) until a steady state was reached ([EthRE IN = [EthFR]OUT

























indicating that ethidium efflux was inhibited (Fig. 6B). Arse-
nate (0.5 mM) and N,N'-dicyclohexylcarbodiimide (0.5 mM)
inhibited ethidium efflux only partially, while sodium azide (0.5
mM) had no effect (data not shown). ortho-Vanadate inhibited
ethidium efflux in DauR and RhoR partially but did not affect
ethidium efflux from the wild-type strain (data not shown).
Since arginine metabolism via the arginine deiminase (ADI)
pathway and the concomitant synthesis ofATP are not affected
by ortho-vanadate, these observations indicate that the efflux
system is ATP driven. Taken as a whole, the experiments with
the metabolic inhibitors indicate that L. lactis is able to express
at least two different (ethidium) efflux activities. One activity is
present in the wild-type strain and forms the major system for
ethidium efflux in DauR and RhoR. This system is coupled to
Ap. The second system is most likely coupled to ATP and is
responsible for ethidium efflux in EthR. This system appears to
play a minor role in the efflux from DauR and RhoR strains.
Daunomycin is a substrate of the L. lactis MDR transport-
ers. Daunomycin fluorescence is quenched upon binding to
polynucleotides, and this property can be used to determine
the internal daunomycin concentration. Efflux of this probe
results in an increase in the fluorescence signal (38). The initial
rate of daunomycin efflux from wild-type cells was increased
upon energization with glucose (25 mM). The daunomycin
efflux rate in EthR was much higher than that in the wild-type
strain (Fig. 7). Similar results were obtained with DauR and
RhoR strains (data not shown). Moreover, as observed for
ethidium efflux, daunomycin efflux was sensitive to valinomycin
and nigericin in wild-type cells but not in EthR cells. These
data indicate that daunomycin is also a substrate of the




FIG. 5. Effect of ionophores and reserpine on ethidium efflux and uptake in L. lactis subsp. lactis MG1363 (wild type) and DauR. (A) MG1363
and DauR cells (0.2 mg of protein per ml) were incubated with 10 ,uM ethidium and subsequently energized with 25 mM glucose (G). Valinomycin
(VAL) and nigericin (NIG) were added to a final concentration of 1 ,uM (lower curve) as indicated. Reserpine (RES) (10-,ug/ml final
concentration) was added prior to incubation with ethidium. The fluorescence intensity after the addition of ethidium and before the addition of
the energy source was normalized to 100%. (B) Uptake of ethidium (1.25 ,uM) in preenergized MG1363 cells (0.1 mg of protein per ml) (NO
ADD.) and in cells preincubated in the presence of nigericin (NIG) or reserpine plus nigericin (RES + NIG) at the same concentrations as for
panel A.
VOL. 176, 1994























FIG. 6. Effect of ionophores, reserpine, and ortho-vanadate on
ethidium efflux and uptake in L. lactis subsp. lactis EthR. (A) EthR cells
(0.2 mg of protein per ml) were incubated with 10 ,uM ethidium and
subsequently energized with 25 mM glucose (G). Valinomycin (VAL)
and nigericin (NIG) were added to a final concentration of 1 p.M
(lower curve) as indicated. Reserpine (RES) (10-p.g/ml final concen-
tration) was added prior to incubation with ethidium. The fluorescence
intensity after the addition of ethidium and before the addition of the
energy source was normalized to 100%. (B) EthR cells were preincu-
bated for 10 min in a phosphate-free buffer (potassium-HEPES [pH
7.0] plus 5 mM MgSO4) supplemented with 0.5 mM ortho-vanadate
(VAN) and were preenergized with L-arginine (10 mM) to allow
ortho-vanadate to enter the cells. The uptake experiment was started
upon the addition of 10 ,uM ethidium. The lower curve represents
ethidium uptake in the absence of ortho-vanadate.
towards daunomycin can be at least partially explained by
increased extrusion of the drug.
DISCUSSION
Mutants of L. lactis subsp. lactis MG1363, termed EthR,
DauR, and RhoR, which display an MDR phenotype have been
isolated and characterized. The mutants were isolated by
selecting for resistance to three structurally unrelated toxic
compounds, i.e., ethidium bromide, daunomycin, and rhoda-
mine 6G. All three mutants showed a similar pattern of
cross-resistance to a variety of unrelated drugs, among which
were typical substrates for the human P-glycoprotein. Analo-
gous to MDR in mammalian cells and different bacteria, the
MDR phenotype in L. lactis is associated with active drug
extrusion. This conclusion is based on measurements of both
the internal and external drug concentrations with fluoromet-
ric assays. Drug efflux in the three MDR mutants is an
energy-dependent enzyme-mediated process as demonstrated
by (i) the stimulation of drug efflux upon energization with
glucose (each mutant exhibited an energy-dependent efflux of
both ethidium and daunomycin which was higher than that in
the wild-type strain) and (ii) drug efflux against a concentration
gradient. The increased resistance of the mutants to ethidium
and daunomycin must be at least partially due to an increase in
extrusion of these compounds. It is likely that the increased
drug extrusion is also responsible for the cross-resistance to the
other compounds tested (e.g., rhodamine 6G, actinomycin D,
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FIG. 7. Daunomycin efflux in L. lactis subsp. lactis MG1363 (wild-
type) and EthR. Daunomycin was added to cell suspensions (0.2 mg of
protein per ml) of L. lactis subsp. lactis MG1363 (wild type) and EthR
to a final concentration of 10 ,uM. Passive influx of daunomycin into
the cells was monitored by measuring the fluorescence decrease
(excitation at 480 nm and emission at 590 nm) as a result of binding of
daunomycin to polynucleotides. After 10 min, the efflux experiment
was started by the adding glucose (G) (25 mM). The maximal
fluorescence intensity immediately following the addition of daunomy-
cin was normalized to 100%. V, valinomycin; N, nigericin.
gramicidin D, and quinine). Increased drug efflux in the
different mutants might be the result of an increased expres-
sion of the systems and/or an increased catalytic efficiency in
transporting the drugs.
Analysis of the energy coupling to ethidium efflux indicates
that in L. lactis more than one transport system can be involved
in the efflux process. Although it cannot be excluded that the
peptide ionophore nigericin (and perhaps valinomycin) is a
substrate of the lactococcal drug efflux system, the observation
that dissipation of the ApH by nigericin and weak acids (e.g.,
acetate) abolishes essentially all efflux activity strongly suggests
that this process is coupled to the ApH. Since dissipation of the
ApH component of the Ap at pH 6.5 is not sufficient to block
ethidium effiux from the wild-type strain completely, an in-
volvement of the A1f in the energy coupling appears most
likely. These observations are best explained by an electrogenic
ethidium/proton antiport system that couples the efflux of
ethidium (carrying one positive charge) to the uptake of at
least two protons. Ethidium extrusion from EthR cells is
inhibited by the phosphate analog ortho-vanadate and not by
nigericin, protonophores, or weak acids that dissipate the Ap
or components thereof. This is indicative of an ATP-depen-
dent transport system. Reserpine, a plant alkaloid which
inhibits the transport catalyzed by the vesicular amine trans-
porter (1), P-glycoprotein (4, 7), and the B. subtilis MDR
carrier (1), also inhibits ethidium efflux in wild-type L. lactis
and in the DauR, RhoR, and EthR strains. Apparently, both the
Ap-driven and the ATP-dependent systems are inhibited by
reserpine, although inhibition of the latter system is less
pronounced than that of the Ap-dependent system. It is worth
noting that drug efflux occurs against a concentration gradient
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in both the wild-type and EthR strains. To dissect the putative
Ap-driven and ATP-dependent drug efflux activities in L. lactis,
a genetic approach is currently being pursued.
The pronounced extrusion activity in the EthR mutant is not
mediated by the previously described ATP-driven 2',7'-bis-(2-
carboxyethyl)-5[and-6]-carboxyfluorescein (BCECF) efflux sys-
tem of L. lactis subsp. lactis MU (30). This conclusion is based
on the observations that the rate of ethidium efflux is not
changed in a mutant which has a fourfold-lowered rate of
BCECF efflux and that the rate of BCECF efflux in the EthR
strain is the same as that in the wild-type (29).
The presence of an ATP-dependent transport system in-
volved in MDR in prokaryotes has not been described before.
The ATP-dependent efflux systems which have been described
for prokaryotes extrude or confer resistance to only a small
range of related compounds (recently reviewed in references 5
and 12). Furthermore, the similarity of these systems to
P-glycoprotein is restricted to highly conserved regions around
the nucleotide-binding motifs (10, 34-36) which bear no direct
relationship to a MDR phenotype. Although the gene(s)
encoding the ATP-dependent ethidium efflux system has not
yet been isolated and a structural similarity cannot be estab-
lished, the lactococcal system has a number of functional
properties in common with P-glycoprotein; i.e., both systems
facilitate the efflux of a wide variety of unrelated drugs and are
inhibited by ortho-vanadate and reserpine.
Multidrug efflux systems in both gram-positive and gram-
negative organisms that are driven by the Ap have been
described previously (23, 31, 39, 42). These energy-dependent
efflux systems are believed to be drug/proton antiporters (17,
23, 31, 41), although solid evidence for such a mechanism is
lacking. The physiological function of the ethidium extrusion
system(s) could be related to a need for the organism to
extrude toxic compounds encountered in the natural habitat,
such as toxins produced by microorganisms or plants. Many of
these compounds are both water and lipid soluble (7, 13).
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